Barrett metaplasia: Reassessment of treatment and follow-up

Current Opinion in Oncology

Volumn 16, Issue 4, 2004, Pages 372-377

  Fitzgerald, R C ^a  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

Ablation therapy; Dysplasia; Esophageal adenocarcinoma; Reflux

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; CELECOXIB; DRINIDENE; ESOMEPRAZOLE; MOLECULAR MARKER; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; SULINDAC SULFONE;

ACID SECRETION; BARRETT ESOPHAGUS; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; DYSPLASIA; ENDOSCOPY; FOLLOW UP; GENE LOCUS; HUMAN; INCIDENCE; INFLAMMATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SURVIVAL RATE; SYMPTOM;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ENDOSCOPES, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; METAPLASIA; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 3042725389     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000128277.07747.5e     Document Type: Review

References (66)

1. Wild CP, Hardie LJ: Reflux, BE and adenocarcinoma: burning questions. Nat Rev Cancer 2003, 3:676-684.
2. Landis SH, Murray T, Bolden S, et al.: Cancer statistics. CA Cancer J Clin 1999, 49:8-31.
3. Berrino F, et al.: Survival of cancer patients in Europe: the EUROCARE-2 study. International Agency for Research on Cancer (IARC), 1999:151.
4. Eloubeidi MA, Provenzale D: Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol 2000, 95:1881-1887.
5. Kulig M, Leodolter A, Vieth M, et al.: Quality of life in relation to symptoms in patients with GORD: an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003, 18:767-776.
6. Kamolz T, Pointner R, Velanovich V: The impact of gastroesophageal reflux disease on quality of life. Surg Endosc 2003, 17:1193-1199.
7. Shaker R, Castell DO, Schoenfeld PS, et al.: Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003, 98:1487-1493.
8. Castell DO: Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994, 89:989-991.
9. Yeh RW, Gerson LB: Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus. Dis Esophagus 2003, 16:193-198.
10. Parrilla P, Martinez de Haro, LF, Ortiz A, et al.: Barrett's esophagus without esophageal stricture does not increase the rate of failure of Nissen fundoplication. Ann Surg 2003, 237:488-493.
11. Papasavas PK, Keenan RJ, Yeaney WW, et al.: Effectiveness of laparoscopic fundoplication in relieving the symptoms of gastroesophageal reflux disease (GERD) and eliminating antireflux medical therapy. Surg Endosc 2003, 17:1200-1205.
12. Gurski RR, Peters JH, Hagen JA, et al.: Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg 2003, 196:706-712 (discussion 712-713). A well-conducted study that sheds light on an area with conflicting published data.
13. Shaheen N, Crosby MA, Bozymski EM, et al.: Is there publication bias in the reporting of cancer risk in Barrett's esophagus. Gastroenterology 2000, 119:333-338.
14. Conio M, Blanchi S, Lapertosa G, et al.: Long-term endoscopic surveillance of patients with Barrett's esophagus: incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003, 98:1931-1939.
15. Murray L, Watson P, Johnston B, et al.: Risk of adenocaroinoma in BE: population based study. Br Med J 2003, 327:534-535. A good-sized population-based study that informs the debate on surveillance.
16. Gopal DV, Lieberman DA, Magaret N, et al.: Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. Dig Dis Sci 2003, 48:1537-1541.
17. Hillman LC, Chiragakis L, Clarke AC, et al.: Barrett's esophagus: macroscopic markers and the prediction of dysplasia and adenocarcinoma. J Gastroenterol Hepatol 2003, 18:526-533.
18. Doak SH, Jenkins GJ, Parry EM, et al.: Chromosome 4 hyperploidy represents an early genetic aberration in premalignant BE. Gut 2003, 52:623-628. An interesting study applying fluorescent in situ hybridization to brushings.
19. Sanz-Ortega J, Hernandez S, Saez MD, et al.: 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia. Hepatogastroenterology 2003, 50:404-407.
20. Suspiro A, Pereira AD, Afonso A, et al.: Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma. Am J Gastraenterol 2003, 98:728-734.
21. Reid BJ, Blount PL, Rabinovitch PS: Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin North Am 2003, 13:369-397.
22. Barrett MT, Pritchard D, Palanca-Wessels C, et al.: Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett's esophagus. Cancer Res 2003, 63:4211-4217.
23. Prevo LJ, Sanchez CA, Galipeau PC, et al.: p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 1999, 59:4784-4787.
24. Dolan K, Walker SJ, Gosney J, et al.: TP53 mutations in malignant and pre-malignant Barrett's esophagus. Dis Esophagus 2003, 16:83-89.
25. Iravani S, Zhang HQ, Yuan ZQ, et al.: Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum Pathol 2003, 34:975-982.
26. Sirieix P, O'Donovan M, Brown J, et al.: Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in BE. Clin Cancer Res 2003, 9:2560-2566. A phase 3 study of a novel proliferation marker that used brushings as well as biopsy specimens.
27. Going JJ, Keith WN, Neilson L, et al.: Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut 2002, 50:373-377.
28. Falk GW: Cytology in Barrett's esophagus. Gastrointest Endosc Clin North Am 2003, 13:335-348.
29. Cappello F, Rappa F, Bucchieri F, et al.: CD1a: a novel biomarker for Barrett's metaplasia? Lancet Oncol 2003, 4:497.
30. Brabender J, Lord RV, Metzger R, et al.: Differential SPARC mRNA expression in BE. Br J Cancer 2003, 89:1508-1512.
31. Breyer HP, Silva de Barros SG, Maguilnik I, et al.: Does methylene blue detect intestinal metaplasia in Barrett's esophagus? Gastrointest Endosc 2003, 57:505-509.
32. Kouklakis GS, Kountouras J, Dokas SM, et al.: Methylene blue chromoendoscopy for the detection of Barrett's esophagus in a Greek cohort. Endoscopy 2003, 35:383-387.
33. Yagi K, Nakamura A, Sekine A: Accuracy of magnifying endoscopy with methylene blue in the diagnosis of specialized intestinal metaplasia and short-segment Barrett's esophagus in Japanese patients without Helicobacter pylori infection. Gastrointest Endosc 2003, 58:189-195.
34. Canto MISS, Willis JE, Chak A, et al.: Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study. Endoscopy 2001, 33:391-400.
35. Olliver JR, Wild CP, Sahay P, et al.: Chromoendoscopy with methylene blue and associated DNA damage in BE. Lancet 2003, 362:373-374. An interesting new twist to be considered by those who advocate the use of methylene blue as a diagnostic tool.
36. Stepinac T, Felley C, Jornod P, et al.: Endoscopic fluorescence detection of intraepithelial neoplasia in Barrett's esophagus after oral administration of aminolevulinic acid. Endoscopy 2003, 35:663-668.
37. Kendall C, Stone N, Shepherd N, et al.: Raman spectroscopy, a potential tool for the objective identification and classification of neoplasia in BE. J Pathol 2003, 200:602-609.
38. Gonzalez-Correa CA, Brown BH, Smallwood RH, et al.: Low frequency electrical bioimpedance for the detection of inflammation and dysplasia in BE. Physiol Meas 2003, 24:291-296.
39. Schnell TG, Sontag SJ, Chejfec G, et al.: Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001, 120:1607-1619.
40. Lundell L: Surgical therapies in Barrett's esophagus. Gastrointest Endosc Clin North Am 2003, 13:433-447.
41. Tseng EE, Wu TT, Yeo CJ, et al.: Barrett's esophagus with HGD: surgical results and long-term outcome - an update. J Gastrointest Surg 2003, 7:164-170 (discussion 170-171).
42. Bonavina L, Via A, Incarbone R, et al.: Results of surgical therapy in patients with Barrett's adenocarcinoma. World J Surg 2003, 27:1062-1066.
43. Romagnoli R, Collard JM, Gutschow C, et al.: Outcomes of dysplasia arising in Barrett's esophagus: a dynamic view. J Am Coll Surg 2003, 197:365-371. A unique prospective, randomized trial of immediate intervention versus continued surveillance/delayed intervention in patients with high-grade dysplasia.
44. Buttar NS, Wang KK, Lutzka LS, et al.: Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001, 120:1630-1639.
45. Dar MS, Goldblum JR, Rice TW, et al.: Can extent of HGD in BE predict the presence of adenocarcinoma at oesophagectomy? Gut 2003, 52:486-489. This paper has important clinical ramifications. The results conflict with previous published results on this subject.
46. Nguyen NT, Roberts P, Follette DM, et al.: Thoracoscopic and laparoscopic esophagectomy for benign and malignant disease: lessons learned from 46 consecutive procedures. J Am Coll Surg 2003, 197:902-913.
47. Seewald S, Akaraviputh T, Seitz U, et al.: Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 2003, 57:854-859.
48. Ackroyd R, Kelty CJ, Brown NJ, et al.: Eradication of dysplastic BE using photodynamic therapy: long-term follow-up. Endoscopy 2003, 35:496-501. These long-term follow-up data have important clinical ramifications.
49. van Hillegersberg R, Haringsma J, ten Kate FJ, et al.: Invasive carcinoma after endoscopic ablative therapy for high-grade dysplasia in BE. Dig Surg 2003, 20:440-444.
50. Overholt BF, Panjehpour M, Halberg DL: Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003, 58:183-188. Much awaited long-term follow-up data on a large prospective series.
51. Hur C, Nishioka NS, Gazelle GS: Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with HGD. Dig Dis Sci 2003, 48:1273-1283.
52. Pagani M, Granelli P, Chella B, et al.: Barrett's esophagus: combined treatment using argon plasma coagulation and laparoscopic antireflux surgery. Dis Esophagus 2003, 16:279-283.
53. Morino M, Rebecchi F, Giaccone C, et al.: Endoscopic ablation of Barrett's esophagus using argon plasma coagulation (APC) following surgical laparoscopic fundoplication. Surg Endosc 2003, 17:539-542.
54. Rudolph RE, Vaughan TL, Kristal AR, et al.: Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus. J Natl Cancer Inst 2003, 95:750-757.
55. Sonnenberg A, Fennerty MB: Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology 2003, 124:1758-1766. A computer modeling approach to evaluate the cost effectiveness of chemoprevention.
56. Desai KM, Soper NJ, Frisella MM, et al.: Efficacy of laparoscopic antireflux surgery in patients with Barrett's esophagus. Am J Surg 2003, 186:652-659.
57. Oelschlager BK, Barreca M, Chang L, et al.: Clinical and pathologic response of Barrett's esophagus to laparoscopic antireflux surgery. Ann Surg 2003, 238:458-464 (discussion 464-466).
58. Parrilla P, Martinez de Haro LF, Ortiz A, et al.: Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003, 237:291-298. A prospective randomized study with long-term follow-up gives interesting insight into a controversial area where data are lacking.
59. Corey KE, Schmitz SM, Shaheen NJ: Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 2003, 98:2390-2394. A thorough meta-analysis, which brings together many data on this subject.
60. Haigh CR, Attwood SE, Thompson DG, et al.: Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003, 124:615-625. The first publication to evaluate the possible negative sequelae of high-dose PPI therapy.
61. Fitzgerald RC, Abdalla S: Gastrin-induced hyperproliferation in Barrett's esophagus. Gastroenterology 2003, 125:1921.
62. Joe AK, Liu H, Xiao D, et al.: Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells. J Exp Ther Oncol 2003, 3:83-94.
63. Bosetti C, Talamini R, Franceschi S, et al.: Aspirin use and cancers of the upper aerodigestive tract. Br J Cancer 2003, 88:672-674. A useful summary of three case-control trials.
64. Corley DA, Kerlikowske K, Verma R, et al.: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124:47-56. A thoughtful meta-analysis and systematic review on chemoprevention.
65. Heath EI, Canto MI, Wu TT, et al.: Chemoprevention for Barrett's esophagus trial: design and outcome measures. Dis Esophagus 2003, 16:177-186.
66. Jankowski J, Sharma P: Approaches to BE treatment: the role of PPI and other interventions. Aliment Pharmacol Ther 2004, 19(Suppl 1):54-59.